AN INTERVENTIONAL PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Latest Information Update: 21 Mar 2023
At a glance
- Drugs Ritlecitinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 20 Mar 2023 This trial has been discontinued in Spain (Global end date: 11 Nov 2022).
- 27 May 2022 New trial record